BioPharmSignal logoBioPharmSignal

Biotech News

Carisma Therapeutics Provides Corporate Updates

Carisma Therapeutics, Inc. (CARM)Carisma Therapeutics, Inc.Company update

Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn PHILADELPHIA , March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has approved a

Related news

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

FATEFate Therapeutics2026-06-15 12:30 EST

Fate Therapeutics Appoints Laura Hamill to Board of Directors

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

View all latest news

Carisma Therapeutics, Inc.

Carisma Therapeutics is a cell-therapy company focused on engineered macrophages and cancer immunotherapy. Its story centers on using a novel immune-cell approach to attack tumors.

Recent company news

CARMCarisma Therapeutics, Inc.2025-12-05 16:16 EST

Carisma Announces Delisting from Nasdaq and SEC Deregistration

CARMCarisma Therapeutics, Inc.2025-03-31 20:30 EST

Carisma Therapeutics Provides Corporate Updates

CARMCarisma Therapeutics, Inc.2025-02-19 12:30 EST

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

CARMCarisma Therapeutics, Inc.2025-02-05 12:30 EST

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

CARMCarisma Therapeutics, Inc.2024-12-09 13:30 EST

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Stock data

Close
0.00 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States